» Articles » PMID: 38110665

A Phase Ib/II Study of Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Plus Anlotinib As First-line Treatment in Patients with Advanced Non-small Cell Lung Cancer

Abstract

Background: Cadonilimab is a bispecific antibody that simultaneously targets programmed cell death receptor-1 and cytotoxic T lymphocyte-associated antigen-4. This study aimed to assess the safety and efficacy of cadonilimab plus anlotinib for the first-line treatment of advanced non-small cell lung cancer (NSCLC) without sensitizing EGFR/ALK/ROS1 mutations.

Methods: Patients received cadonilimab 15 mg/kg and 10 mg/kg every three weeks (Q3W) plus anlotinib at doses of 10 or 12 mg once daily for two weeks on a one-week-off schedule. The primary endpoints included safety and objective response rate (ORR).

Results: Sixty-nine treatment-naïve patients received cadonilimab 15 mg/kg Q3W combination (n = 49) and 10 mg/kg Q3W combination (n = 20). Treatment-related adverse events (TRAEs) were reported in 48 (98.0%) and 19 (95.0%) patients, with grade ≥3 TRAEs occurring in 29 (59.2%) and five (25.0%) patients, respectively. TRAEs leading to cadonilimab discontinuation occurred in eight (16.3%) and one (5.0%) patients in the cadonilimab 15 mg/kg Q3W and 10 mg/kg Q3W dosing groups. The confirmed ORRs were 51.0% (25/49) and 60.0% (12/20) accordingly.

Conclusions: Cadonilimab 10 mg/kg Q3W plus anlotinib showed manageable safety and promising efficacy as a first-line chemo-free treatment for advanced NSCLC.

Clinicaltrials:

Gov Identifier: NCT04646330.

Citing Articles

Case report: Therapeutic response of front-line cadonilimab plus chemotherapy on patient with advanced lung adenocarcinoma harboring STK11 genetic aberration.

Feng D, Jiang H, Chen G, Guan W, Yi L, Zhu Y Front Immunol. 2024; 15:1485358.

PMID: 39717770 PMC: 11663897. DOI: 10.3389/fimmu.2024.1485358.


A surprising complete response to cadonilimab in a primary metastatic cervical cancer: a case report.

Yu H, Lin J, Chen J, Chen L, Zou J, Liu B Front Immunol. 2024; 15():1494138.

PMID: 39660134 PMC: 11628523. DOI: 10.3389/fimmu.2024.1494138.


Next-generation immunotherapy: igniting new hope for lung cancer.

Li M, Chan A, Mok K, Chan L, Mok T Ther Adv Med Oncol. 2024; 16:17588359241302021.

PMID: 39649017 PMC: 11624561. DOI: 10.1177/17588359241302021.


Advances in the Management of Lung Cancer Brain Metastases.

Hockemeyer K, Rusthoven C, Pike L Cancers (Basel). 2024; 16(22.

PMID: 39594735 PMC: 11593022. DOI: 10.3390/cancers16223780.


Good response to cadonilimab as first-line treatment in superaged patient with advanced gastric cancer: a case report.

Lun J, Ma G, Wang X, Wang Q Immunotherapy. 2024; 16(16-17):1015-1019.

PMID: 39258789 PMC: 11492687. DOI: 10.1080/1750743X.2024.2394405.


References
1.
Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

2.
Nicholson A, Tsao M, Beasley M, Borczuk A, Brambilla E, Cooper W . The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. J Thorac Oncol. 2021; 17(3):362-387. DOI: 10.1016/j.jtho.2021.11.003. View

3.
Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. View

4.
Mok T, Wu Y, Kudaba I, Kowalski D, Cho B, Turna H . Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019; 393(10183):1819-1830. DOI: 10.1016/S0140-6736(18)32409-7. View

5.
Herbst R, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios C . Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. N Engl J Med. 2020; 383(14):1328-1339. DOI: 10.1056/NEJMoa1917346. View